TNF SNP | Erosive v non-erosive if RF positive by 5 years (n = 166) | Erosive v non-erosive if RA defined by ACR criteria by 5 years (n = 343) | ||
---|---|---|---|---|
OR (99% CI)‡ | p Value‡ | OR (99% CI)‡ | p Value‡ | |
The two subgroups shown are patients with IP who are RF positive by 5 years and patients who satisfy ACR classification criteria for RA by 5 years | ||||
†OR of having an erosive outcome in the presence of the rare allele except for TNF-308*G/A where the odds ratio relates to presence of the common TNF-308*G allele; ‡analysis has been adjusted to account for possible confounding by treatment. | ||||
TNF−1031*C/T | 1.00 (0.44 to 2.26) | 1.00 | 1.44 (0.85 to 2.45) | 0.08 |
TNF−863*C/A | 1.17 (0.52 to 2.66) | 0.62 | 1.55 (0.88 to 2.74) | 0.05 |
TNF−857*C/T | 1.18 (0.39 to 3.57) | 0.71 | 1.02 (0.51 to 2.03) | 0.95 |
TNF−376*G/A | 0.19 (0.01 to 3.43) | 0.14 | 1.95 (0.48 to 7.89) | 0.22 |
TNF−308*G/A† | 1.38 (0.53 to 3.62) | 0.39 | 1.49 (0.83 to 2.66) | 0.08 |
TNF−238*G/A | 0.59 (0.11 to 3.21) | 0.42 | 1.36 (0.49 to 3.76) | 0.44 |
TNF+489*G/A | 0.89 (0.28 to 2.88) | 0.80 | 1.19 (0.60 to 2.35) | 0.51 |
TNF+851*A/G | 0.46 (0.05 to 4.11) | 0.36 | 1.45 (0.55 to 3.78) | 0.32 |
TNF+1304*A/G | 1.84 (0.47 to 7.20) | 0.25 | 1.12 (0.52 to 2.42) | 0.70 |